Skip to search formSkip to main contentSkip to account menu

AP24534

Known as: AP 24534, AP-24534 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ponatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
The N 550 K / H Mutations in FGFR 2 Confer Differential Resistance to PD 173074 , Dovitinib , and Ponatinib ATP-Competitive Inhibitors 1
We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR… 
2013
2013
Abstract 2084: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC .
Background: RET kinase is dysregulated by activating mutations or fusion gene formation in multiple cancers, including medullary… 
2012
2012
Ponatinib for chronic myeloid leukemia.
The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the… 
2012
2012
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients 
2011
2011
Abstract 3560: Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: Members of the fibroblast growth factor… 
2011
2011
Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants
Abstract 930 Background: Activating mutations in FLT3 are detected in approximately 30 percent of adult acute myeloid leukemia… 
2010
2010
Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.
6511 Background: AP24534, an oral multiple tyrosine kinase inhibitor (TKI), is a potent pan-BCR-ABL inhibitor, including T315I. A… 
2010
2010
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036
Abstract 3398 Chronic Myeloid Leukemia (CML) treatment was radically modified by the discovery of imatinib (IM), a selective… 
2008
2008
Inhibitors of ABL and the ABL-T315I mutation.
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder caused by increased and unregulated growth of myeloid… 
2008
2008
Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor
The BCR-ABL inhibitor imatinib is front-line therapy for chronic myeloid leukemia (CML). The second-line inhibitors dasatinib and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)